Eli Lilly: The Worst May Be Already Over (Earnings Preview)
Summary
Eli Lilly (LLY) is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5....
Eli Lilly (LLY) is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Analysts expect continued volume-driven revenue and margin expansion, with consensus seeing EPS and sales growth well above industry averages through 2026. LLY's Q1 saw 45% revenue growth but a minor EPS miss due to IPR&D charges; management reaffirmed full-year guidance, and volume growth is expected to offset price erosion.
Related Articles
Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease
LLY
Positive3 Dividend Growth Stocks You Can Buy and Forget About
LLY
PositiveLilly sees obesity drug leadership beyond US as it leans on consumer-focused strategy
LLY
Neutral